Cargando…
Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database
Information on immune checkpoint inhibitor-induced vasculitides is limited, and predictors for this condition have not been identified. Therefore, we have examined the frequency of immune checkpoint inhibitor-induced vasculitides by analyzing the data recorded in the Japanese Adverse Drug Event Repo...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992371/ https://www.ncbi.nlm.nih.gov/pubmed/35401222 http://dx.doi.org/10.3389/fphar.2022.803706 |
_version_ | 1784683716480598016 |
---|---|
author | Kato, Koki Mizuno, Tomohiro Koseki, Takenao Ito, Yoshimasa Takahashi, Kazuo Tsuboi, Naotake Yamada, Shigeki |
author_facet | Kato, Koki Mizuno, Tomohiro Koseki, Takenao Ito, Yoshimasa Takahashi, Kazuo Tsuboi, Naotake Yamada, Shigeki |
author_sort | Kato, Koki |
collection | PubMed |
description | Information on immune checkpoint inhibitor-induced vasculitides is limited, and predictors for this condition have not been identified. Therefore, we have examined the frequency of immune checkpoint inhibitor-induced vasculitides by analyzing the data recorded in the Japanese Adverse Drug Event Report database. Data from April 2004 to March 2020 were extracted, and vasculitides as an immune-related adverse event was defined according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Adverse event signals were recognized as significant when the reporting odds ratio estimates and lower limits of the corresponding 95% confidence intervals exceeded 1. The use of nivolumab showed a significant signal for vasculitides. Furthermore, significant signals of polymyalgia rheumatica were found when the patients were treated with nivolumab, pembrolizumab, and ipilimumab. In addition, the frequencies of nivolumab- and pembrolizumab-induced polymyalgia rheumatica were higher in patients aged ≥70 years and female patients, respectively. Polymyalgia rheumatica was reported in 38 patients treated with nivolumab; 31 (82%) of these were either in recovery or in remission. Further, polymyalgia rheumatica was reported in 17 patients treated with pembrolizumab; 13 (76%) of these were in recovery or remission, while three (18%) were not. Polymyalgia rheumatica was reported in 12 patients treated with ipilimumab; seven (58%) of these were in recovery or remission. Our study highlights that careful monitoring for the symptom of PMR (e.g., bilateral pain in shoulder and pelvic girdles) is required when the patients are aged >70 years and have been treated with nivolumab and when the patients are women and have been treated with pembrolizumab. |
format | Online Article Text |
id | pubmed-8992371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89923712022-04-09 Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database Kato, Koki Mizuno, Tomohiro Koseki, Takenao Ito, Yoshimasa Takahashi, Kazuo Tsuboi, Naotake Yamada, Shigeki Front Pharmacol Pharmacology Information on immune checkpoint inhibitor-induced vasculitides is limited, and predictors for this condition have not been identified. Therefore, we have examined the frequency of immune checkpoint inhibitor-induced vasculitides by analyzing the data recorded in the Japanese Adverse Drug Event Report database. Data from April 2004 to March 2020 were extracted, and vasculitides as an immune-related adverse event was defined according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Adverse event signals were recognized as significant when the reporting odds ratio estimates and lower limits of the corresponding 95% confidence intervals exceeded 1. The use of nivolumab showed a significant signal for vasculitides. Furthermore, significant signals of polymyalgia rheumatica were found when the patients were treated with nivolumab, pembrolizumab, and ipilimumab. In addition, the frequencies of nivolumab- and pembrolizumab-induced polymyalgia rheumatica were higher in patients aged ≥70 years and female patients, respectively. Polymyalgia rheumatica was reported in 38 patients treated with nivolumab; 31 (82%) of these were either in recovery or in remission. Further, polymyalgia rheumatica was reported in 17 patients treated with pembrolizumab; 13 (76%) of these were in recovery or remission, while three (18%) were not. Polymyalgia rheumatica was reported in 12 patients treated with ipilimumab; seven (58%) of these were in recovery or remission. Our study highlights that careful monitoring for the symptom of PMR (e.g., bilateral pain in shoulder and pelvic girdles) is required when the patients are aged >70 years and have been treated with nivolumab and when the patients are women and have been treated with pembrolizumab. Frontiers Media S.A. 2022-03-25 /pmc/articles/PMC8992371/ /pubmed/35401222 http://dx.doi.org/10.3389/fphar.2022.803706 Text en Copyright © 2022 Kato, Mizuno, Koseki, Ito, Takahashi, Tsuboi and Yamada. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Kato, Koki Mizuno, Tomohiro Koseki, Takenao Ito, Yoshimasa Takahashi, Kazuo Tsuboi, Naotake Yamada, Shigeki Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database |
title | Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database |
title_full | Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database |
title_fullStr | Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database |
title_full_unstemmed | Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database |
title_short | Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database |
title_sort | frequency of immune checkpoint inhibitor-induced vasculitides: an observational study using data from the japanese adverse drug event report database |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992371/ https://www.ncbi.nlm.nih.gov/pubmed/35401222 http://dx.doi.org/10.3389/fphar.2022.803706 |
work_keys_str_mv | AT katokoki frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase AT mizunotomohiro frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase AT kosekitakenao frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase AT itoyoshimasa frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase AT takahashikazuo frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase AT tsuboinaotake frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase AT yamadashigeki frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase |